Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Gwénaëlle Gravis, Karim Fizazi, Florence Joly, +29

The Lancet Oncology

Androgen-deprivation TherapyUrologyGenitourinary CancerMedicineGetug-afu 15 +5

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

Gwénaëlle Gravis, Jean‐Marie Boher, Florence Joly, +16

European Urology

UrologyGenitourinary CancerGetug-afu15 TrialMedicineAndrogen Deprivation Therapy +5

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Davide Melisi, Rocio García‐Carbonero, Teresa Macarulla, +14

British Journal of Cancer

Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study

Thierry Conroy, B Paillot, Éric François, +10

Journal of Clinical Oncology

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Karim Fizazi, Laura Faivre, F. Lesaunier, +27

The Lancet Oncology

UrologyGetug 12Genitourinary CancerMedicineAndrogen Deprivation Therapy +6

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial

Jean-Philippe Durand, G. Deplanque, Vincent Montheil, +10

Annals of Oncology

PharmacologyClinical TrialsClinical PharmacologyOxaliplatin-induced Acute NeurotoxicityNeuroprotection +3

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

Thierry André, Déwi Vernerey, Laurent Mineur, +25

Journal of Clinical Oncology

Dfs EventsSurgical OncologyOncologyPurpose ReductionGastrointestinal Oncology +12

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann, +183

The Lancet Oncology

MedicineMetronomic TherapyGynecologyRecurrent Ovarian CancerCancer Treatment +6

Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2

Stéphane Oudard, Stéphane Culine, Yann Vano, +19

European Journal of Cancer

UrologyMetastatic Urothelial CarcinomaPhase Ii TrialGenitourinary CancerMedicine +4

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial

Aude Fléchon, Damien Pouessel, Céline Ferlay, +11

Annals of Oncology

UrologyGenitourinary CancerMedicineP01 TrialPhase Ii Study +4